Richard A. Colvin is Chief Medical Officer at bluebird bio, Inc. (BLUE). They have made 9 open-market trades across 1 company since 2022, most recently 2025-06-02.
CIK 0001944069
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BLUE | 4,166 | $21K |
Shares reported on the most recent Form 4, priced at the 2025-06-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BLUE | SELL | 2025-03-03 | 2025-03-05 | $3.92 | $2K | +1.5% | +26.9% | N/A |
| BLUE | SELL | 2025-02-03 | 2025-02-05 | $7.39 | $473 | +1.3% | -43.1% | -45.4% |
| BLUE | SELL | 2025-01-06 | 2025-01-08 | $9.24 | $176 | -6.9% | -25.3% | -42.8% |
| BLUE | SELL | 2024-12-10 | 2024-12-12 | $0.42 | $1K | +3.0% | +12.3% | -48.9% |
| BLUE | SELL | 2024-03-01 | 2024-03-05 | $1.53 | $10K | -0.7% | -14.0% | -32.6% |
| BLUE | SELL | 2024-01-05 | 2024-01-09 | $1.42 | $848 | -8.6% | -24.5% | -16.5% |
| BLUE | SELL | 2023-11-02 | 2023-11-03 | $2.98 | $7K | -7.1% | +26.3% | -71.8% |
| BLUE | SELL | 2023-01-11 | 2023-01-13 | $7.80 | $4K | -19.8% | -23.3% | -57.9% |
| BLUE | SELL | 2022-11-04 | 2022-11-08 | $6.41 | $1K | -3.1% | +8.9% | -7.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.